From:
Extensive Media Enterprises
A milestone for Florida State University: The first families have been enrolled in the Sunshine Genetics pilot program at its Florida Institute for Pediatric Rare Diseases (IPRD). The program uses whole-genome sequencing to screen newborns for nearly 900 rare genetic conditions. Early identification of these conditions empowers families with knowledge about their newborn, reduces diagnostic delays and accelerates the path to treatment or specialized management. “Two years ago, this was an idea we were fighting to make a reality. Today, Florida families can enroll their newborns in a program we once could only imagine. This remarkable progress is a testament to the doctors, researchers and industry leaders, as well as the hospitals and universities across Florida and around the country, who believed in this vision and worked to make it possible,” said Rep. Adam Anderson, who helped champion the legislation that established both the IPRD and Sunshine Genetics Act. Anderson also delivered a keynote address at the International Consortium of Newborn Sequencing (ICoNS) this week at Harvard Medical School before an international collection of experts in the field. He was joined by IPRD and Sunshine Genetics leadership as well as leaders from many of the program’s partners. IPRD administers Sunshine Genetics, with guidance from its steering committee and support from Baylor Genetics, GeneDx, Nest Genomics and Amazon Web Services. “Enrolling our first families enables us to begin the carefully coordinated approach to implementing a statewide genomic newborn screening program responsibly,” said IPRD Director Pradeep Bhide. “The steering committee and participating organizations have worked together to establish the governance, clinical and laboratory workflows, quality safeguards and lines of accountability needed to support every stage of the program, from enrollment and consent to sequencing, interpretation, results disclosure and recommendations for follow-up care.” GeneDx was one of IPRD’s first major industry partners. Its contributions to efforts to find cures for rare pediatric genetic diseases include strategic and operational guidance during the lead-up to the Sunshine Genetics launch. 
The first Sunshine Genetics Pilot Program families and their newborns enrolled. Image via Chris Condon/FSU College of Medicine. The program’s gene list is also derived from the BRIDGES-NBS program, developed in partnership with GeneDx. “We believe genomics should be a starting point for health, not a last resort after years of searching for answers,” said Linda Genen, chief medical officer at GeneDx. “We’re proud to bring our deep clinical and genomic expertise to help guide programs like this, ensuring they are designed to deliver meaningful, actionable information for clinicians and families. Florida is demonstrating what’s possible when state leaders, academic institutions and genomic experts work together to thoughtfully integrate genomics into care and give more families a clearer path forward from the very beginning.” Although Sunshine Genetics will create a data resource to support research, discovery and innovation in the diagnosis and treatment of pediatric rare diseases, the program is also committed to keeping families’ and participants’ data private and not shareable. The program says it is committed to protecting participant privacy while developing a research data resource. AWS is helping make the database secure and scalable so it can collect and store genomic and clinical data that will accelerate the diagnosis and treatment of pediatric rare diseases. AWS will also help turn that data into actionable insights that could fuel discovery and drive innovation. A new era of precision medicine could be here, thanks to FSU, IPRD, and the partners and sponsors who make it a reality. “The Sunshine Genetics pilot is unique in the United States as the only project initiated and funded by the state Legislature, with the express goal of generating evidence to determine whether this should be expanded to benefit all 225,000 babies born each year in Florida,” said David Ledbetter, IPRD’s senior associate director of precision medicine. “We are excited to be working with our outstanding genetics and newborn screening expert colleagues at the University of Miami, University of South Florida, University of Florida, children’s hospitals in the state and our world-class industry partners.” For more information about this program, visit the Sunshine Genetics website or Florida Institute for Pediatric Rare Diseases website. ___ Coming up, the usual assortment of news, intel, and observations from the week that was in Florida's capital city by Peter Schorsch, Drew Wilson, Drew Dixon, Liam Fineout and the staff of Florida Politics. But first, the "Takeaway 5" — the Top 5 stories from the week that was: |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.